Trial Confirms That Perjeta Extends Survival In Metastatic Breast Cancer
Perjeta extends survival in patients with Her2 positive breast cancer. Might drugs targeting Her2 be effective in other malignancies?
An angiotensin-converting enzyme (ACE) inhibitor and β-blocker prevented cardiotoxicity associated with combination chemotherapy in women with ERBB2 (formerly HER2)–positive breast cancer, reported a trial in the Journal of the American College of Cardiology.
The recent arrival of CDK4/6 inhibitor agents, with an approximate doubling of progression-free survival associated with their use in hormone receptor-positive, HER2-negative advanced breast cancer, has radically changed the approach to managing this disease. However, resistance to CDK4/6 inhibitors is considered a near-inevitability in most patients. Mechanisms of resistance to these agents are multifactorial, and research in this field is still evolving. Biomarkers with the ability to identify early resistance, or to predict the likelihood of successful treatment using CDK4/6 inhibitors are yet to be identified, and repr...
A 72-year-old woman presented with 2-month history of “bruises” on the left breast. She was treated for a left breast cancer 6 years earlier. She previously had stage IA (cT1cN0M0) invasive ductal carcinoma that was estrogen receptor/progesterone receptor positive and Her2 negative. She underwent partial mastectomy and sentinel lymph node biopsy th at confirmed stage pT1cN0. In the setting of bilateral silicone breast implants, she received adjuvant partial breast irradiation to 36 Gy in 9 fractions twice daily, targeting the seroma with 1.5 to 2 cm margins.
ConclusionsAmong breast cancer patients, nearly one-third exhibit clinical-pathological stage discordance. This high likelihood of discordance is important to consider for counseling and treatment planning.
yong-Huey Lai Endometrial cancer incidence rates are growing, especially in countries with rapid socioeconomic transitions. Despite recent advances in chemotherapy, hormone therapy, and targeted therapy, advanced/recurrent disease remains a clinical challenge. Palbociclib—a selective inhibitor of cyclin-dependent kinases (CDK) 4/6—has therapeutic potential against estrogen receptor (ER)-positive and HER2-negative breast cancer. However, the question as to whether it can be clinically useful in endometrial cancer remains open. Here, we show that combined treatment with palbociclib and megesterol acet...
CONCLUSIONS: In patients with ER-positive, HER2-negative breast cancer, adding taxane to an anthracycline regimen did not improve DFS in patients with metastasis in 1-3 lymph nodes. We considered that the group without the addition of taxane might be present in patients with ER-positive, HER2-negative lymph node metastases. PMID: 31327134 [PubMed - as supplied by publisher]
A trial presented at ASCO 2019 found HER2 heterogenity can impact response rates to some treatments in HER2-positive breast cancer patients.
Oncogene, Published online: 19 July 2019; doi:10.1038/s41388-019-0893-4FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis
CONCLUSION: Residual nodal disease after NAC analysed by LNRC or LNR = 0.25 cut-off value, is prognostic and can discriminate between favourable and unfavourable outcomes for TNBC and Her2+ breast cancers.
Condition: HER2-positive Early Breast Cancer Interventions: Drug: Pertuzumab IV; Drug: Trastuzumab IV; Drug: FDC of Pertuzumab and Trastuzumab SC; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Docetaxel; Procedure: Surgery; Radiation: Post-Operative Radiotherapy; Drug: Hormone Therapy Sponsor: Hoffmann-La Roche Not yet recruiting